Verteporfin therapy for choroidal hemangioma: a long-term follow-up.
To document the long-term follow-up of patients with circumscribed choroidal hemangioma who were treated with verteporfin photodynamic therapy (PDT). Fifteen patients were included in a prospective interventional case series. Verteporfin PDT as a bolus infusion of 6 mg/m body surface area and a light dose of 100 J/cm at 689 nm applied over 166 seconds were administered. Standardized evaluation was performed every 3 months within the first year and at 12-month intervals during follow-up. At baseline, all patients presented with significant vision loss ranging from 20/26 to 20/500. During a mean follow-up of 36.6 months (range, 12-66 months), no patient had evidence of recurrence. Mean final visual acuity ranged from 20/20 to 20/400. In all patients, complete and permanent regression with no signs of tumor regrowth or recurring subretinal fluid was found. Of 15 patients, 13 had a substantial increase in visual acuity (range, 2-9 lines), and 2 patients' visual acuity remained stable. Chorioretinal atrophy at the previous tumor site did not enlarge over time. Retreatments after completion of the primary treatment were not necessary. Persistent and complete absence of choroidal hemangioma associated with persistent improvement in visual acuity and central visual fields can be obtained with verteporfin PDT.